Aphton: Neue Nachrichten! - 500 Beiträge pro Seite

[Patagonier]

Beim der Aktie Aphton (APHT) kam heute morgen in den USA eine neue Meldung, die besagt, daß Aphton die Zulassung zur Durchführung klinischer Studien für ein Antikrebsmittel erhalten hat. Die Meldung kann über Yahoo abgerufen werden.

Hier besteht die Möglichkeit, noch vorher in Deutschland zu kaufen.

Dies ist kein Pushversuch, ich weiß auch nicht, ob sich das auf den Kurs positiv auswirken wird.

Grüße vom Patagonier

[Patagonier]

Und wieder was neues:

Friday March 24, 6:00 am Eastern Time
Company Press Release

Increased Survival Results of Advanced Pancreatic Cancer Patients in Phase II Clinical Trial Announced by Aphton

BIRMINGHAM, United Kingdom--(BW HealthWire)-- March 24, 2000--At the annual meeting of the British Society of Gastroenterology held in Birmingham, UK, on March 21-23, 2000, Aphton Corporation (NASDAQ/NMS:APHT - news) and collaborating scientists presented results showing increased survival in advanced pancreatic cancer patients treated with Aphton`s anti-gastrin therapeutic vaccine.

The results are from a Phase II dose-ranging clinical trial conducted by clinical investigators in the UK. The study consisted of 30 evaluable patients, all of whom had advanced pancreatic cancer. With the primary objective of the study being dose ranging, patients were divided into lower-dose and higher-dose treatment groups. All patients in the trial received Aphton`s anti-gastrin vaccine, with no additional or concurrent therapies.

Overall median survival of the 30 evaluable patients was 6.7 months. This median survival compares favorably with published data showing median survival of approximately 4.3 months for patients with advanced pancreatic cancer who either receive no additional therapies or do not respond to additional therapies for their disease. The overall median survival of the patients treated with Aphton`s anti-gastrin vaccine (both responders and non-responders) was 56% greater than the baseline median survival of 4.3 months.

A further analysis showed that among those patients responding to Aphton`s anti-gastrin vaccine, median survival increased to 7.3 months. This was 70% greater than the baseline median survival. A patient was considered to be a responder to Aphton`s anti-gastrin therapy if any antibody response was detected. Approximately 30% of patients responded to the vaccine at the low-dose levels and approximately 80% of patients responded to the higher-dose levels. The immune responders had the same clinical status as the immune non-responders. Thus, the likeliest difference in survival is due to the immune responsiveness of the patients.

Aphton`s anti-gastrin therapy was well tolerated with no systemic toxicity. Two patients gained weight, in a disease where the hallmark is a continuous loss of weight.

Aphton`s anti-gastrin vaccine induces antibodies in patients that neutralize (block) the central growth factor in pancreatic cancer, gastrin-17. This neutralization of gastrin-17 slows the proliferation and spread of pancreatic cancer. Aphton plans to commence a pivotal Phase III clinical trial in the U.S. in patients with advanced pancreatic cancer in the coming months.

It is estimated that approximately 88,000 new cases of pancreatic cancer will be diagnosed in the US and Europe this year. The prognosis for most of these patients is very poor. The great majority of patients have advanced disease at the time of diagnosis and are considered incurable, with a very short median survival time. In the US, patients diagnosed with pancreatic cancer (all stages) have five-year survival rates of only four percent. Surgery, when possible, and chemotherapy are the primary treatment options currently available, but have shown only very limited benefit. Aphton believes that its anti-gastrin vaccine approach has the potential to extend patient survival in a non-toxic manner.

Aphton Corporation is a biopharmaceutical company developing products using its innovative vaccine-like technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and non-cancer diseases; and the prevention of pregnancy. Aphton has strategic alliances with Aventis Pasteur (formerly Pasteur Merieux Connaught, Rhone-Poulenc Group), SmithKline Beecham PLC, Schering Plough Animal Health and the World Health Organization (WHO).

Except for the historical information herein, the matters discussed herein include forward-looking statements that may involve a number of risks and uncertainties. Future results may vary significantly based on a number of factors including, but not limited to, intellectual property risks, risks in regulatory and market acceptance of new products and continuing demand for same, the impact of competitive products and pricing, changing economic conditions and other risk factors detailed in Aphton`s most recent 10-K and other filings with the Securities and Exchange Commission.

[Patagonier]

Tatsächlich steigt der Kurs zur Zeit steil an: 45 US $

Grüße auch an Masterman001 !

[Masterman001]

Hi Patagonier!

jeztz wird es heiß. Patagonier will angeblich Techniclone und Creative Bio... übernehmen. ( s. dazu siliconinvestor). Kursziel auf 70$ in 6 Monaten angehoben. Der Global Biotech Investor spricht sogar von 150$

[Patagonier]

" ... Patagonier will angeblich Techniclone und Creative ... übernehmen..."

Ich weiß nichts von einer geplanten Übernahme meinerseits von Techniclone und Creative Biomulecules. Alle Gerüchte dazu sind frei erfunden. Nach Abzug von Miete und weiteren Kosten, mußte ich sämtliche Versuche feindlicher Übernahmen vorerst auf Eis legen. Aber vielleicht schaffen wir es ja zusammen, Mastermann001

[toothstone]

Eigentlich wollte ich ja die beiden Pharmaunternehmen schlucken, vielleicht sind aber doch zu dritt die Chancen am größten. Leider haben die 45 noch nicht gehalten. Aphton kämpft noch mit seinem Widerstand bei 40 Dollar.

[Masterman001]

Friday December 8, 6:08 am Eastern Time

Press Release

Aphton to Commence Colorectal Cancer Clinical Trial
in US With Patients Who Have Failed Approved
Chemotherapy

MIAMI--(BW HealthWire)--Dec. 8, 2000--Aphton (Nasdaq:APHT - news), a company with products in pivotal and
late-stage clinical trials for cancer therapy, is commencing a clinical trial with patients who have failed the approved
chemotherapy regimen (5-FU and irinotecan) for the treatment of colorectal cancer, stage Dukes` D. Patients will be treated
with a combination regimen of Aphton`s anti-G17 immunogen and irinotecan. Aphton plans to file for a ``fast track`` marketing
approval when a sufficient number of such ``chemo-refractive`` terminal patients respond to the treatment.

Aphton is now in the process of enlisting clinical trial sites and investigators in the US to participate in this trial, which is being
conducted under an IND in place with the US FDA. Aphton is also evaluating the design and timing of a similar trial in Europe.

Aphton is also currently conducting pivotal and other advanced phase clinical trials in the US and Europe for pancreatic,
colorectal and gastric cancer patients. (See previous Aphton news releases.)

Colorectal cancer is the second most common cause of cancer death in the Western world. Its rate of incidence increases
steeply with age. Presently, in the US alone, there are an estimated 760,000 people with diagnosed colorectal cancer, with
more than 130,000 new cases being diagnosed yearly. Of the 760,000 patient total, over 40% are expected to die within the
next 5 years. A large majority of the approximately 60,000 patients who will die during the year 2000 (as estimated by the
American Cancer Society) will have been treated with chemotherapy that failed when they became unresponsive, a condition
referred to as chemo-refractory. With the prognosis so grim, the need for improved colorectal cancer therapy, particularly for
chemo-refractory patients, is large and urgent.

Aphton`s anti-gastrin therapy represents a unique, non-toxic and innovative biological treatment for patients suffering from
gastrointestinal system cancers. Aphton`s anti-gastrin drug induces a directed antibody response against gastrin and other
gastrin-related growth factors. Gastrin has been established as a central hormonal growth factor that stimulates gastrointestinal
cancer cells to proliferate and spread.

Aphton Corporation is a biopharmaceutical company in late-stage, pivotal Phase III clinical trials. Aphton is developing
products using its innovative vaccine-like technology for neutralizing, and removing from circulation, hormones that participate in
gastrointestinal system and reproductive system diseases, both cancer and non-cancer. Aphton is also developing products for
neutralizing hormones to prevent pregnancy. Aphton has strategic alliances with Aventis Pasteur (NYSE:AVE - news),
SmithKline Beecham PLC (NYSE:SBH - news), Schering Plough Animal Health (NYSE:SGP - news) and the World Health
Organization (WHO).

Except for the historical information herein, the matters discussed herein include forward-looking statements that may involve a
number of risks and uncertainties. Future results may vary significantly based on a number of factors including, but not limited
to, intellectual property risks, risks in regulatory and market acceptance of new products and continuing demand for same, the
impact of competitive products and pricing, changing economic conditions and other risk factors detailed in Aphton`s most
recent 10-K and other filings with the Securities and Exchange Commission.